panitumumab
amgen,takeda
modified folfoxiri plus panitumumab (mfolfoxiri/pan) versus mfolfox6/pan as initial treatment of unresectable ras/braf wild-type metastatic colorectal cancer (mcrc) patients: results of the phase iii randomized triplete study by gono #wgiesmo2022
Medical Oncologist at Hospital Virgen del Rocío, Seville. GI Malignancies. The University of Chicago (Fellow). Mom. First I drink coffee, then I do many things